FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Forest Laboratories Saphris 10 mg Recall

Saphris 10 mg (asenapine) sublingual tablets, 6x10 count blister packs, Rx only, Black…

Forest Laboratories, LLC · Jersey City, NJ

Risk level
Class II
Reported by FDA
Jun 7, 2017
Recall ID
D-0880-2017
Check your lot numberHow we source this data

Summary

Forest Laboratories recalled Saphris 10 mg starting May 18, 2017. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0880-2017 on Jun 7, 2017. Reason: Labeling; Label Mixup; blister lidding foil and shell-pack labeled as 10 mg but package actually contains 5 mg tablets. Status: Terminated.

Why it was recalled

Labeling; Label Mixup; blister lidding foil and shell-pack labeled as 10 mg but package actually contains 5 mg tablets

Product description

Saphris 10 mg (asenapine) sublingual tablets, 6x10 count blister packs, Rx only, Black Cherry Flavor, Manufactured by: Catalent UK Swindon, Zydis Ltd, Blagrove, Swindon, Wilshire SN5 BRU, UK Distributed by Forest Pharmaceuticals, Inc. subsidiary of Forest Laboratories, LLC, Cincinnati OH 45209 USA --- NDC 0456-2410-60; Shellpack containing 1 blister card --- NDC 0456-2410-06

Lot numbers, UPCs & expiration codes

Lots W00733 and W00946, exp Apr 2019

Where it was sold

Nationwide

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0880-2017
Classification
Class II
Status
Terminated
Recall initiated
May 18, 2017
FDA report date
Jun 7, 2017
Quantity
40,621 blister packs
Recall type
Voluntary: Firm initiated
Recalling firm
Forest Laboratories, LLC

Original FDA data

Every field from FDA enforcement report D-0880-2017, exactly as published.

Show all FDA fields
City
Jersey City
State
NJ
Status
Terminated
Country
United States
Event ID
77315
Address
Harborside Financial Center
Address (line 2)
Plaza V- Suite 1900
Code information
Lots W00733 and W00946, exp Apr 2019
Postal code
07311
Report date
Jun 7, 2017
Product type
Drugs
Recall number
D-0880-2017
Classification
Class II
Recalling firm
Forest Laboratories, LLC
Product quantity
40,621 blister packs
Termination date
Nov 15, 2018
Reason for recall
Labeling; Label Mixup; blister lidding foil and shell-pack labeled as 10 mg but package actually contains 5 mg tablets
Voluntary / mandated
Voluntary: Firm initiated
Product description
Saphris 10 mg (asenapine) sublingual tablets, 6x10 count blister packs, Rx only, Black Cherry Flavor, Manufactured by: Catalent UK Swindon, Zydis Ltd, Blagrove, Swindon, Wilshire SN5 BRU, UK Distributed by Forest Pharmaceuticals, Inc. subsidiary of Forest Laboratories, LLC, Cincinnati OH 45209 USA --- NDC 0456-2410-60; Shellpack containing 1 blister card --- NDC 0456-2410-06
Distribution pattern
Nationwide
Recall initiation date
May 18, 2017
Initial firm notification
Letter
Center classification date
May 31, 2017

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0880-2017, published Jun 7, 2017. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls